Logo image of PYXS

PYXIS ONCOLOGY INC (PYXS) Stock Fundamental Analysis

NASDAQ:PYXS - Nasdaq - US7473241013 - Common Stock - Currency: USD

1.26  +0.16 (+14.55%)

After market: 1.26 0 (0%)

Fundamental Rating

2

Overall PYXS gets a fundamental rating of 2 out of 10. We evaluated PYXS against 567 industry peers in the Biotechnology industry. The financial health of PYXS is average, but there are quite some concerns on its profitability. PYXS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PYXS had negative earnings in the past year.
PYXS had a negative operating cash flow in the past year.
PYXS had negative earnings in each of the past 5 years.
PYXS had a negative operating cash flow in each of the past 5 years.
PYXS Yearly Net Income VS EBIT VS OCF VS FCFPYXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

PYXS has a Return On Assets (-49.20%) which is in line with its industry peers.
PYXS has a Return On Equity (-64.04%) which is in line with its industry peers.
Industry RankSector Rank
ROA -49.2%
ROE -64.04%
ROIC N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
PYXS Yearly ROA, ROE, ROICPYXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Gross Margin of PYXS (97.06%) is better than 96.11% of its industry peers.
The Profit Margin and Operating Margin are not available for PYXS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYXS Yearly Profit, Operating, Gross MarginsPYXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

PYXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PYXS has more shares outstanding
PYXS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PYXS has a worse debt to assets ratio.
PYXS Yearly Shares OutstandingPYXS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PYXS Yearly Total Debt VS Total AssetsPYXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -2.58, we must say that PYXS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.58, PYXS perfoms like the industry average, outperforming 51.24% of the companies in the same industry.
PYXS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
PYXS's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. PYXS outperforms 48.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.58
ROIC/WACCN/A
WACC10.05%
PYXS Yearly LT Debt VS Equity VS FCFPYXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 7.49 indicates that PYXS has no problem at all paying its short term obligations.
PYXS's Current ratio of 7.49 is fine compared to the rest of the industry. PYXS outperforms 71.73% of its industry peers.
PYXS has a Quick Ratio of 7.49. This indicates that PYXS is financially healthy and has no problem in meeting its short term obligations.
PYXS's Quick ratio of 7.49 is fine compared to the rest of the industry. PYXS outperforms 71.91% of its industry peers.
Industry RankSector Rank
Current Ratio 7.49
Quick Ratio 7.49
PYXS Yearly Current Assets VS Current LiabilitesPYXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.65% over the past year.
EPS 1Y (TTM)48.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PYXS will show a decrease in Earnings Per Share. The EPS will decrease by -3.52% on average per year.
Based on estimates for the next years, PYXS will show a very strong growth in Revenue. The Revenue will grow by 44.71% on average per year.
EPS Next Y-20.25%
EPS Next 2Y-2.58%
EPS Next 3Y-6.02%
EPS Next 5Y-3.52%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-18.78%
Revenue Next 5Y44.71%

3.3 Evolution

PYXS Yearly Revenue VS EstimatesPYXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
PYXS Yearly EPS VS EstimatesPYXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PYXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PYXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYXS Price Earnings VS Forward Price EarningsPYXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYXS Per share dataPYXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A cheap valuation may be justified as PYXS's earnings are expected to decrease with -6.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.58%
EPS Next 3Y-6.02%

More info and screens

0

5. Dividend

5.1 Amount

PYXS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PYXIS ONCOLOGY INC

NASDAQ:PYXS (5/2/2025, 8:18:42 PM)

After market: 1.26 0 (0%)

1.26

+0.16 (+14.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18 2025-03-18/bmo
Earnings (Next)05-09 2025-05-09/bmo
Inst Owners41.24%
Inst Owner Change0%
Ins Owners7.68%
Ins Owner Change0%
Market Cap77.60M
Analysts85.71
Price Target7.34 (482.54%)
Short Float %15.24%
Short Ratio12.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.11%
Min EPS beat(2)-9.51%
Max EPS beat(2)25.73%
EPS beat(4)3
Avg EPS beat(4)26.06%
Min EPS beat(4)-9.51%
Max EPS beat(4)75.69%
EPS beat(8)6
Avg EPS beat(8)25.71%
EPS beat(12)6
Avg EPS beat(12)11.58%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.38%
PT rev (3m)-26.96%
EPS NQ rev (1m)-1.03%
EPS NQ rev (3m)10.61%
EPS NY rev (1m)1.47%
EPS NY rev (3m)7.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.81
P/FCF N/A
P/OCF N/A
P/B 0.64
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0.26
BVpS1.96
TBVpS1.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.2%
ROE -64.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.06%
FCFM N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.95%
Cap/Sales 1.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.49
Quick Ratio 7.49
Altman-Z -2.58
F-Score4
WACC10.05%
ROIC/WACCN/A
Cap/Depr(3y)419.47%
Cap/Depr(5y)331.27%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.24%
EPS Next Y-20.25%
EPS Next 2Y-2.58%
EPS Next 3Y-6.02%
EPS Next 5Y-3.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-18.78%
Revenue Next 5Y44.71%
EBIT growth 1Y16.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-192.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.44%
OCF growth 3YN/A
OCF growth 5YN/A